// Md. Asaduzzaman Khan 1, 2 , Mousumi Tania 3 , Shangyi Fu 4 and Junjiang Fu 1 1 Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China 2 Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam 3 Division of Computer Aided Drug Design, The Red-Green Computing Centre, Dhaka, Bangladesh 4 The Honors College, University of Houston, Houston, Texas, United States Correspondence to: Junjiang Fu, email: fujunjiang@swmu.edu.cn , fujunjiang@hotmail.com Md. Asaduzzaman Khan, email: asadkhan@swmu.edu.cn , asadkhanbmj@yahoo.com Keywords: Nigella sativa, thymoquinone, anticancer, mouse model, clinical studies Received: March 13, 2017 Accepted: April 05, 2017 Published: April 18, 2017 ABSTRACT Thymoquinone is an anticancer phytochemical commonly found in black cumin. In this review, we discuss the potential of thymoquinone as anticancer molecule, its mechanism of action and future usage in clinical applications. Thymoquinone exhibits anticancer activity via numerous mechanisms of action, specifically by showing selective antioxidant and oxidant activity, interfering with DNA structure, affecting carcinogenic signaling molecules/pathways and immunomodulation. In vitro activity of thymoquinone has been further implicated in animal models of cancer; however, no clinical application has been proven yet. This is the optimum time to focus on clinical trials for developing thymoquinone as a future drug in cancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: